Ftse Mib
34.339,32
0,55%
DAX
18.686,60
1,07%
S&P 500
5.214,08
0,51%
NASDAQ
16.346,26
0,27%
Bitcoin
62.944,56
-0,16%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Canada TSX Oncolytics Biotech Inc (ONC) Oncolytics Biotech Inc (ONC) Notizie

ONC

Oncolytics Biotech (ONC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:TSX:ONC
DataOraFonteTitoloSimboloCompagnia
26/09/202314:00PR Newswire (US)THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTSTSX:ONCOncolytics Biotech Inc
01/06/202218:23PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - ONC.WTTSX:ONCOncolytics Biotech Inc
01/06/202218:21PR Newswire (Canada)IIROC Trading Halt - ONC.WTTSX:ONCOncolytics Biotech Inc
10/01/202217:57PR Newswire (US)New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024TSX:ONCOncolytics Biotech Inc
09/04/202117:56PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - ONCTSX:ONCOncolytics Biotech Inc
09/04/202117:56PR Newswire (Canada)IIROC Trade Resumption - ONCTSX:ONCOncolytics Biotech Inc
09/04/202117:53PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - ONCTSX:ONCOncolytics Biotech Inc
09/04/202117:52PR Newswire (Canada)IIROC Trading Halt - ONCTSX:ONCOncolytics Biotech Inc
27/12/201713:00PR Newswire (US)Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patien...TSX:ONCOncolytics Biotech Inc
05/12/201713:00PR Newswire (US)Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic B...TSX:ONCOncolytics Biotech Inc
04/12/201713:00PR Newswire (US)Oncolytics Biotech® to Present at the Oncolytic Virotherapy SummitTSX:ONCOncolytics Biotech Inc
30/11/201713:00PR Newswire (US)Oncolytics Biotech® Establishes Scientific Advisory Board Focused on REOLYSIN® Registration Study in Metastatic Breast Canc...TSX:ONCOncolytics Biotech Inc
16/11/201723:00PR Newswire (Canada)Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®TSX:ONCOncolytics Biotech Inc
08/11/201713:00PR Newswire (US)Oncolytics Biotech® Inc. Announces 2017 Third Quarter ResultsTSX:ONCOncolytics Biotech Inc
02/11/201712:00PR Newswire (US)Oncolytics Biotech® Appoints Deborah Brown to Board of DirectorsTSX:ONCOncolytics Biotech Inc
11/10/201713:00PR Newswire (US)Oncolytics Biotech® to Present at the 2017 BIO Investor ForumTSX:ONCOncolytics Biotech Inc
19/09/201713:00PR Newswire (US)Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers ConferenceTSX:ONCOncolytics Biotech Inc
18/09/201713:00PR Newswire (US)Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast CancerTSX:ONCOncolytics Biotech Inc
14/09/201713:00PR Newswire (US)Oncolytics Biotech® Announces First Patient Treated in MUK eleven StudyTSX:ONCOncolytics Biotech Inc
11/09/201713:00PR Newswire (US)Oncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESMO 2017 CongressTSX:ONCOncolytics Biotech Inc
03/08/201713:00PR Newswire (US)Oncolytics Biotech® Inc. Announces 2017 Second Quarter ResultsTSX:ONCOncolytics Biotech Inc
01/08/201713:00PR Newswire (US)Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth ConferenceTSX:ONCOncolytics Biotech Inc
26/07/201713:00PR Newswire (US)Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 CongressTSX:ONCOncolytics Biotech Inc
29/06/201713:00PR Newswire (Canada)Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (U.S.) Inc.TSX:ONCOncolytics Biotech Inc
27/06/201713:00PR Newswire (US)Oncolytics Biotech® Inc. Opens U.S. Based Office in San DiegoTSX:ONCOncolytics Biotech Inc
01/06/201715:44PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - ONC.WTTSX:ONCOncolytics Biotech Inc
01/06/201715:43PR Newswire (Canada)IIROC Trade Resumption - ONC.WTTSX:ONCOncolytics Biotech Inc
01/06/201715:27PR Newswire (US)Oncolytics Biotech® Announces Closing of Public Offering of UnitsTSX:ONCOncolytics Biotech Inc
24/05/201716:39PR Newswire (US)Oncolytics Biotech® Prices Public Offering of UnitsTSX:ONCOncolytics Biotech Inc
24/05/201701:09PR Newswire (US)Oncolytics Biotech® Announces Proposed Public OfferingTSX:ONCOncolytics Biotech Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:TSX:ONC

La tua Cronologia

BIT
BPE
Bper Banca
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
NEXI
Nexi S.p.A
BIT
BAMI
Banco BPM
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
PRY
Prysmian
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
FBK
Finecobank
BIT
TIT
Telecom Italia
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network